Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
Discontinued
Reference number: GID-TA10271
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid October 2018.